Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: investor (5)

Dr. Tyler Korman, co-founder and VP of Research at eXoZymes, is excited about the 'exozymes' cover story in GEN Biotechnology, which is freely available as an Open Access paper.
press releaseinvestorvideoscience
GEN Biotechnology cover story: Bringing clarity and precision to the cell-free space by introducing exozymesApril 21, 2025
Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler Korman
investorpress clippingsvideoscience
Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler KormanApril 15, 2025
BioClick - an enzyme engineering game-changer
press releaseinvestorscience
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grantApril 10, 2025
World Bio Market Insights: eXoZymes appoints Damien Perriman as Chief Commercial Officer
investorpress clippings
World Bio Market Insights: eXoZymes appoints Damien Perriman as Chief Commercial OfficerApril 3, 2025
Transcript: eXoZymes 4th quarter and full Year 2024 update from April 2, 2025
investor
Transcript: eXoZymes 4th quarter and full Year 2024 update from April 2, 2025April 3, 2025
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
talentpress releaseinvestorvideo
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCOApril 2, 2025
eXoZymes Provides Fourth Quarter and Full Year 2024 Update
press releaseinvestor
eXoZymes Provides Fourth Quarter and Full Year 2024 UpdateApril 2, 2025
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025
press releaseIPOinvestor
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025March 26, 2025
Fox Business: Interview with Chief Market Strategist, Lou Basenese
investorpress clippingsvideo
Fox Business: Interview with Chief Market Strategist, Lou BaseneseMarch 17, 2025
ARCHIVE: Fox Business: Interview with CEO Michael Heltzen
heltzeninvestorpress clippingsvideoARCHIVE
ARCHIVE: Fox Business: Interview with CEO Michael HeltzenMarch 3, 2025
Previous page
Page 5 of 8
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark